An unusual case of mesalazine intoxication: Oral and rectal overloading of the rectal suppository form

Human and Experimental Toxicology

Volumn 30, Issue 7, 2011, Pages 772-776

  Koseoglu, Zikret ^a   Satar, Salim ^a   Kara, Banu ^a   Sebe, Ahmet ^b   Kosenli, Ozgun ^a  

^a ADANA NUMUNE EDUCATION AND RESEARCH HOSPITAL   (Turkey)

^b CUKUROVA UNIVERSITY   (Turkey)

Author keywords

clinical toxicology; gastrointestinal toxicology; human toxicology

Indexed keywords

ACTIVATED CARBON; MESALAZINE;

ADULT; ARTICLE; CASE REPORT; COLONOSCOPY; DEPRESSION; DIZZINESS; DRUG INTOXICATION; DRUG OVERDOSE; EDEMA; HEADACHE; HUMAN; HYPEREMIA; INTESTINE ULCER; MALE; NAUSEA; PRIORITY JOURNAL; SUICIDE ATTEMPT; SUPPOSITORY; ULCERATIVE COLITIS;

ADMINISTRATION, ORAL; ADMINISTRATION, RECTAL; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTI-ULCER AGENTS; CHARCOAL; COLITIS, ULCERATIVE; COLONOSCOPY; FLUID THERAPY; GASTRIC LAVAGE; HUMANS; MALE; MESALAMINE; OVERDOSE; POISONING; SUCRALFATE; SUICIDE, ATTEMPTED; SUPPOSITORIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79959703528     PISSN: 09603271     EISSN: 14770903     Source Type: Journal    
DOI: 10.1177/0960327110379249     Document Type: Article

References (28)

1. Cohen HD, Das KM The metabolism of Mesalamine and it's possible use in colonic diverticulitis as an anti-inflammatory agent. J Clin Gastroenterol 2006 ; 40: 150-154.
2. Loftus EV Jr, Kane SV, and Bjorkman D. Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis. Aliment Pharmacol Ther 2004 ; 19: 179-189. (Pubitemid 38174887)
3. Karagozian R., Burakoff R. The role of mesalamine in the treatment of ulcerative colitis. Ther Clin Risk Manag 2007 ; 3: 893-903. (Pubitemid 350162088)
4. Tursi A., Brandimarte G., Giorgetti GM, Forti G., Modeo ME, and Gigliobianco A. Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis. Med Sci Monit 2004 ; 10: 126-131.
5. D'Haens G., van Bodegraven AA Mesalazine is safe for the treatment of IBD. GUT 2004 ; 53: 155.
6. Cortot A., Maetz D., Degoutte E., Delette O., Meurier P., et al. Meselamine foam enema versus meselamine liquid enema in active left sided ulcerative colitis. Am J Gastroenterol 2008 ; 103: 3106-3114.
7. Minocha A., Dean HA Jr, and Mayle JE Acute sulfasalazine overdose. J Toxicol Clin Toxicol 1991 ; 29: 543-551.
8. Tindall WN New approaches to adherence issues when dosing oral aminosalicylates in ulcerative colitis. Am J Health Syst Pharm 2009 ; 66: 451-457.
9. Kaiser GC, Yan F., and Polk DB Mesalamine blocks tumor necrosis factor growth inhibition and nuclear factor kappaB activation in mouse colonocytes. Gastroenterology 1999 ; 116: 602-609. (Pubitemid 29106768)
10. Pastorini E., Locatelli M., Simoni P., Roda G., Roda E., and Roda A. Development and validation of a HPLC-ESI-MS/MS method for the determination of 5-aminosalicylic acid and its major metabolite N-acetyl-5-aminosalicylic acid in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2008 ; 872: 99-106.
11. Egan LJ, Mays DC, Huntoon CJ, et al. Inhibition of interleukin-1- stimulated NF-kappaB RelA/p65 phosphorylation by mesalamine is accompanied by decreased transcriptional activity. J Biol Chem 1999 ; 274: 26448-26453.
12. Hanauer SB Review article: aminosalicylates in infl ammatory bowel ulcerative colitis. Aliments Pharmacol Ther 2004 ; 20: 60-65.
13. Bachrach WH Sulfasalazine: an historical perspective. Am J Gastroenterol 1988 ; 83: 487-496.
14. Das KM, Eastwood MA, McManus JPA, and Sircus W. Adverse reactions during salicy lazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype. N Eng J Med 1973 ; 289: 491-495.
15. Hanauber SB Review article: high dose aminosalicylates to induce and maintain remissions in ulcerative colitis. Aliment Pharmacol Ther 2006 ; 24: 37-40.
16. Desreumax P., Chosh S. Review article: mode of action and delivery of 5-aminosalicyclic acid, new evidince. Aliment Pharmacol Ther 2006 ; 24: 2-9.
17. Watkinson G. Sulfasalazine: a review of 40 years experience. Drugs 1986 ; 32: 1-11.
18. Green JR, Lobo AJ, Holdsworth CD, Leicester RJ, Gibson JA, Kerr GD, et al. Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis. The Abacus Investigator Group. Gastroenterology 1998 ; 114: 15-22. (Pubitemid 28020949)
19. Rahimi R., Nikfar S., Rezaie A., and Abdollahi M. Comparison of mesalazine and balsalazide in induction and maintenance of remission in patients with ulcerative colitis: a meta-analysis. Dig Dis Sci 2009 ; 54: 712-721.
20. Gearry RB, Ajlouni Y., Nandurkar S., Iser JH, and Gibson PR 5-aminosalicylic acid (mesalazine) use in Crohn's disease: a survey of the opinions and practice of Australian gastroenterologists. Inflamm Bowel Dis 2007 ; 13: 1009-1015. (Pubitemid 47309973)
21. Gionchetti P., Rizzello F., Venturi A., Ferretti M., Brignola C., Miglioli M., et al. Comparison of oral with rectal mesalazine in the treatment of ulcerative proctitis. Dis Colon Rectum 1998 ; 41: 93-97. (Pubitemid 28044882)
22. Topical 5-aminosalicylic acid versus prednisolone in ulcerative proctosigmoiditis. A randomized double-blind multicenter trial. Danish 5-ASA Group Study. Dis Dis Sci 1987 ; 32: 598-602.
23. Kruis W., Schreiber S., Theuer D., Brandes JW, Schütz E., Howaldt S., et al. Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses. Gut 2000: 49: 783-789. (Pubitemid 33096035)
24. Zinberg J., Molinas S., and Das KM Double blinded, placebo controlled clinical study of olsalazine in the treatment of symptomatic ulcerative colitis. Am J Gastroenterol 1990 ; 85: 562-566. (Pubitemid 20164314)
25. Das KM Sulfasalazine therapy in inflammatory bowel disease. Gastroenterol Clin N Am 1989 ; 18: 1-20. (Pubitemid 19077644)
26. Powell-Tuck J., MacRae KD, Healy MJR, Lennard-Jones JE, and Parkins RA A defence of the small clinical trial: evaluation of three gastroenterological studies. Br Med J 1986 ; 292: 599-602. (Pubitemid 16139710)
27. Marshall JK, Irvine EJ Rectal aminosalicylate therapy for distal ulcerative colitis: a meta-analysis. Aliment Pharmacol Ther 1995 ; 9: 293-300.
28. Brogden RN, Sorkin EM Mesalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in chronic inflammatory bowel disease. Drugs 1989 ; 38: 500-523. (Pubitemid 19258559)